AFP (Alpha-Fetoprotein - Liver Cancer)
Marker for liver cancer
1 providers include this
Cancer Screening Markers
<10 ng/mL, Elevated:>400 ng/mL suggests cancer
What is AFP (Alpha-Fetoprotein - Liver Cancer)?
Marker for liver cancer
Why It Matters
Elevated in hepatocellular carcinoma (liver cancer) and germ cell tumors. Used for screening in high-risk patients and monitoring treatment.
Which Providers Test AFP (Alpha-Fetoprotein - Liver Cancer)?
Full Provider Comparison
| Provider | Includes | Annual Cost | Biomarkers |
|---|---|---|---|
| — | $199 | 100+ (150 with ratios) | |
| — | $349 | 65 | |
| — | $398 | 30+ | |
| — | $486 | 40+ | |
| — | $444 | 288 | |
| — | $349 | 100+ | |
| — | $761 | 54 | |
| ✓ | $365 | 160+ | |
| — | $250 | 65 | |
| — | $495 | 70+ | |
| — | $895 | 100+ | |
| — | $1950 | 150+ | |
| — | $375 | 80+ | |
| — | $Varies | 75+ | |
| — | $190 | 100+ | |
| — | $99 | 50 | |
| — | $124 | 60 | |
| — | $199 | 50 | |
| — | $499 | 120+ | |
| — | $4188 | 70-80+ | |
| — | $375 | 85 | |
| — | $700 | 128 |
Frequently Asked Questions
What is AFP (Alpha-Fetoprotein - Liver Cancer)?
Marker for liver cancer
What is the optimal range for AFP (Alpha-Fetoprotein - Liver Cancer)?
The standard reference range for AFP (Alpha-Fetoprotein - Liver Cancer) is <10 ng/mL, Elevated:>400 ng/mL suggests cancer. Optimal ranges may differ based on individual health goals and expert recommendations.
Which blood test providers include AFP (Alpha-Fetoprotein - Liver Cancer)?
1 out of 22 blood testing providers include AFP (Alpha-Fetoprotein - Liver Cancer) in their panels. This biomarker has limited availability.
What category does AFP (Alpha-Fetoprotein - Liver Cancer) fall under?
AFP (Alpha-Fetoprotein - Liver Cancer) is categorized under Cancer Screening Markers. This category includes biomarkers that help assess related aspects of health and wellness.
Medical Disclaimer
This information is for educational purposes only and is not medical advice. Always consult with a qualified healthcare provider about your specific health needs.
Last reviewed:2026-02-20